苯巴比妥治疗新生儿黄疸的对照试验。
Controlled trial of phenobarbitone in neonatal jaundice.
作者信息
Levin G E, McMullin G P, Mobarak A N
出版信息
Arch Dis Child. 1970 Feb;45(239):93-6. doi: 10.1136/adc.45.239.93.
A single-blind controlled trial of phenobarbitone in the treatment of non-obstructive neonatal jaundice is reported. 24 babies were given phenobarbitone by mouth for 3 days from the first appearance of jaundice. 27 babies were given placebo linctus for the same period from the appearance of jaundice. There was a small but statistically significant difference between the mean serum bilirubin levels of the two groups 24 hours after starting treatment or placebo, the mean level of the control group being the higher. There was no significant difference in the mean serum bilirubin levels for the two groups initially or at 48 and 72 hours. The maximum recorded levels of serum bilirubin did not differ significantly between the two groups. It is concluded that phenobarbitone has no place in the management of established neonatal jaundice.
本文报道了苯巴比妥治疗非梗阻性新生儿黄疸的单盲对照试验。24例婴儿自黄疸初现起口服苯巴比妥3天。27例婴儿自黄疸出现起同期给予安慰剂糖浆。开始治疗或服用安慰剂24小时后，两组的平均血清胆红素水平存在微小但具有统计学意义的差异，对照组的平均水平较高。两组最初、48小时和72小时时的平均血清胆红素水平无显著差异。两组血清胆红素的最高记录水平无显著差异。结论是苯巴比妥在已确诊的新生儿黄疸治疗中无应用价值。
Zotero 插件